文献速递MDS 与骨髓增殖性肿瘤血栓与止血

细胞因子通路变异调控血小板生成:IFNA16是人类血小板增多症的易感位点

Cytokine pathway variants modulate platelet production: IFNA16 is a thrombocytosis susceptibility locus in humans.
PubMed 文献 · Blood Adv · 2022-01-01

研究采用候选基因策略,在反应性血小板增多症(RT)和原发性血小板增多症(ET)队列中分析326个多态性基因,发现IFNA16的两个单核苷酸变异与ET相关,并在独立队列中验证(P=.0002)。合并ET队列(n=105)的比值比为4.92,JAK2V617F阴性亚组为5.01;变异型IFNA16携带者IFN-α16水平显著升高(P=.002)。

要点

  • IFNA16的两个单核苷酸变异与原发性血小板增多症(ET)相关,独立队列验证P=.0002。
  • 合并ET队列(n=105)比值比4.92,JAK2V617F阴性亚组比值比5.01。
  • 变异型IFNA16者IFN-α16水平较非携带者显著升高(P=.002)。

核心结论

  • IFNA16(IFN-α16基因产物)可能是MPN中广泛紊乱的细胞因子网络内的一个易感位点(驱动因素)。

研究设计与样本

  • 采用候选基因策略靶向326个富集于血小板生成和细胞因子信号通路的多态性基因,在反应性血小板增多症(RT)或原发性(骨髓增殖性肿瘤)血小板增多症(ET)队列中鉴定与血小板反应增强相关的单核苷酸变异。
  • ET关联在第二独立队列中验证(P=.0002)。
  • 合并ET队列样本量为n=105。

主要发现

  • 包含15个成员子集的细胞因子谱、通路拓扑和功能交互网络在ET与RT之间不同,与二者血小板生成过度的调控通路不同相一致。
  • 聚合(ET+RT)或ET限制性队列的遗传学研究鉴定出与2个IFNA16(干扰素-α16)单核苷酸变异的关联。
  • 合并ET队列(n=105)的比值比为4.92,限制于JAK2V617F阴性亚组时比值比为5.01。
  • 按IFNA16变异进行ET亚分层分析,在16个可定量细胞因子中IFN-α16水平呈统计学显著升高(P=.002)。
  • 重组表达的变异型IFN-α16包含3个连锁非同义单核苷酸变异(E65H95P133),其抗病毒和pSTAT信号谱与天然IFN-α16(V65D95A133)或IFN-α2相当,但天然和变异型IFN-α16在CD34+刺激的巨核细胞中均显示IFN调节基因的阶段限制性差异(与IFN-α2相比)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inflammatory stimuli have divergent effects on peripheral platelet counts, although the mechanisms of thrombocytopenic and thrombocytotic responses remain poorly understood. A candidate gene approach targeting 326 polymorphic genes enriched in thrombopoietic and cytokine signaling pathways was applied to identify single nucleotide variants (SNVs) implicated in enhanced platelet responses in cohorts with reactive thrombocytosis (RT) or essential (myeloproliferative neoplasm [MPN]) thrombocytosis (ET). Cytokine profiles incorporating a 15-member subset, pathway topology, and functional interactive networks were distinct between ET and RT, consistent with distinct regulatory pathways of exaggerated thrombopoiesis. Genetic studies using aggregate (ET + RT) or ET-restricted cohorts identified associations with 2 IFNA16 (interferon-α16) SNVs, and the ET associations were validated in a second independent cohort (P = .0002). Odds ratio of the combined ET cohort (n = 105) was 4.92, restricted to the JAK2V617F-negative subset (odds ratio, 5.01). ET substratification analysis by variant IFNA16 exhibited a statistically significant increase in IFN-α16 levels (P = .002) among 16 quantifiable cytokines. Recombinantly expressed variant IFN-α16 encompassing 3 linked non-synonymous SNVs (E65H95P133) retained comparable antiviral and pSTAT signaling profiles as native IFN-α16 (V65D95A133) or IFN-α2, although both native and variant IFN-α16 showed stage-restricted differences (compared with IFN-α2) of IFN-regulated genes in CD34+-stimulated megakaryocytes. These data implicate IFNA16 (IFN-α16 gene product) as a putative susceptibility locus (driver) within the broader disrupted cytokine network evident in MPNs, and they provide a framework for dissecting functional interactive networks regulating stress or MPN thrombopoiesis.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gnatenko DV, Liu Z, Hearing P, et al. Cytokine pathway variants modulate platelet production: IFNA16 is a thrombocytosis susceptibility locus in humans. Blood Adv. 2022. PMID: 35381074. doi:10.1182/bloodadvances.2021005648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。